5-METHOXY-N,N-DIMETHYLTRYPTAMINE (5-MEO-DMT) FOR TREATING MAJOR DEPRESSION

(19)

(11)

EP 3 927 337 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	20.03.2024 Bulletin 2024/12

(45)	Mention of the grant of the patent:
	14.02.2024 Bulletin 2024/07

(21)	Application number: 20710059.5

(22)	Date of filing: 24.02.2020

(51)

International Patent Classification (IPC):

A61K 31/4045^(2006.01)

A61P 25/24^(2006.01)

(52)	Cooperative Patent Classification (CPC):
	A61K 31/4045; A61P 25/24

(86)	International application number:
	PCT/EP2020/054803

(87)	International publication number:
	WO 2020/169850 (27.08.2020 Gazette 2020/35)

(54)	5-METHOXY-N,N-DIMETHYLTRYPTAMINE (5-MEO-DMT) FOR TREATING MAJOR DEPRESSION 5-METHOXY-N,N-DIMETHYLTRYPTAMINE (5-MEO-DMT) ZUR BEHANDLUNG VON SCHWEREN DEPRESSION 5-METHOXY-N,N-DIMETHYLTRYPTAMINE (5-MEO-DMT) POUR LE TRAITEMENT DE LA DEPRESSION MAJEURE

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
	Designated Extension States:
	BA ME
	Designated Validation States:
	KH MA MD TN

(30)

Priority:

22.02.2019 EP 19158774

(43)	Date of publication of application:
	29.12.2021 Bulletin 2021/52

(60)	Divisional application:
	24157388.0
	24157425.0

(73)	Proprietor: GH Research Ireland Limited
	D02 RY95 Dublin 2 (IE)

(72)	Inventor:
	TERWEY, Theis 10119 Berlin (DE)

(74)	Representative: Breuer, Markus et al
	Sendlinger Straße 29 80331 München 80331 München (DE)

(56)

References cited: :

WO-A1-2018/195455

WO-A1-2019/081764

UTHAUG MALIN V ET AL: "Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment", PSYCHOPHARMACOLOGY, SPRINGER VERLAG, BERLIN, DE, vol. 237, no. 3, 10 December 2019 (2019-12-10), pages 773-785, XP037030419, ISSN: 0033-3158, DOI: 10.1007/S00213-019-05414-W [retrieved on 2019-12-10]
OSÓRIO FDE L ET AL: "Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report", REVISTA BRASILEIRA DE PSIQUIATRIA, PUBL. SOLUTIONS, BR, vol. 37, no. 1, 1 January 2015 (2015-01-01), pages 13-20, XP009520464, ISSN: 1516-4446, DOI: 10.1590/1516-4446-2014-1496
THOMAS G ET AL: "Ayahuasca-assisted therapyfor addiction: results from a preliminary observational study in Canada", CURRENT DRUG ABUSE REVIEWSE, BENTHAM SCIENCE PUBLISHERS LTD, vol. 6, no. 1, 1 March 2013 (2013-03-01), pages 30-42, XP009520465, ISSN: 1874-4737, DOI: 10.2174/15733998113099990003
GEYER M A ET AL: "Behavioural and pharmacological studies of pharmahuasca in rodents", EUROPEAN NEUROPSYCHOPHARMACOLOGY, vol. 26, 2016, XP029787110, ISSN: 0924-977X, DOI: 10.1016/S0924-977X(16)30889-6
CARHART-HARRIS R L ET AL: "Psilocybin with psychological support for treatment-resistant depression: six-month follow-up", PSYCHOPHARMACOLOGY, SPRINGER VERLAG, BERLIN, DE, vol. 235, no. 2, 8 November 2017 (2017-11-08), pages 399-408, XP036477494, ISSN: 0033-3158, DOI: 10.1007/S00213-017-4771-X [retrieved on 2017-11-08]
SHEN HONG-WU ET AL: "Nonlinear Pharmacokinetics of 5-Methoxy-N,N-dimethyltryptamine in Mice", DRUG METABOLISM AND DISPOSITION, PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, US , vol. 39, no. 7 30 June 2011 (2011-06-30), pages 1227-1234, XP009520579, ISSN: 0090-9556, DOI: 10.1124/DMD.111.039107 Retrieved from the Internet: URL:http://dmd.aspetjournals.org/cgi/doi/1 0.1124/dmd.111.039107
ALAN K. DAVIS ET AL: "5-methoxy- N,N -dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety", AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, vol. 45, no. 2, 1 March 2019 (2019-03-01), pages 161-169, XP055695498, US ISSN: 0095-2990, DOI: 10.1080/00952990.2018.1545024

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).